Loading...
Market
For which condition will Merck's CN201 therapy be used by December 31, 2025?
2
Resolution / Starting Odds
B-cell malignancies • 25%
Autoimmune diseases • 25%
Both • 25%
Neither • 25%
Official press release from Merck or FDA announcements
Story
Merck to Acquire CN201 Therapy from Curon for $700M, Plus Earnouts
Aug 9, 2024, 10:55 AM
Merck has announced its acquisition of the investigational B-cell depletion therapy CN201 from Curon Biopharmaceutical. The deal includes an upfront payment of $700 million in cash, with potential earnouts of up to $600 million. This acquisition is part of Merck's strategy to expand its pipeline, particularly in the areas of B-cell malignancies and autoimmune diseases. The therapy, described as a novel investigational bispecific antibody, is expected to enhance Merck's offerings in these therapeutic areas.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
More than $1 billion • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Lung fibrosis • 25%
Age-related diseases • 25%
Cancer • 25%
Other • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Less than $100 million • 25%
$100 million to $299 million • 25%
$300 million to $499 million • 25%
$500 million or more • 25%
Yes • 50%
No • 50%
Positive results for B-cell malignancies • 25%
Positive results for autoimmune diseases • 25%
Negative results for both • 25%
Mixed results • 25%